Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/22/2005US20050281841 antigen is expressed from Salmonella enterica serovar Typhi strain Ty21a; gene cluster operably linked to transcriptional promoter and termination signals; for protecting the host against bacillary dysentery and shigellosis; immunotherapy
12/22/2005US20050281837 Immunologically active peptides with altered toxicity useful for the preparation of antipertussis vaccine
12/22/2005US20050281836 Synthetic vaccine for tick control
12/22/2005US20050281835 Polypeptide and polynucleotide of given sequences; monoclonal antibody binding to antigen Ag473; use in vaccines and diagnosis
12/22/2005US20050281834 Altered peptide ligands
12/22/2005US20050281832 Methods of enhancing immune response in the intradermal compartment and compounds useful thereof
12/22/2005US20050281831 inhibiting vascularization or angiogenesis using chimeric proteins, immunoglobulin-like domains of tyrosine kinase receptors
12/22/2005US20050281830 Detection, prevention, and treatment systems for anthrax
12/22/2005US20050281829 Fc chimeric proteins with anti-HIV drugs
12/22/2005US20050281828 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/22/2005US20050281827 Trypanosome derived apoptotic factors (TAF)
12/22/2005US20050281826 Therapeutic agent for iNOS generating illness cross-references to related applications
12/22/2005US20050281824 Methods of using IMXP-888 and IMXP-888 antagonists
12/22/2005US20050281822 Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
12/22/2005US20050281821 Binds to a denatured collagens but not to native triple helical forms of the collagen; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists
12/22/2005US20050281820 Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives
12/22/2005US20050281818 Method for the treatment of fibrosis
12/22/2005US20050281817 Method for treating multiple sclerosis
12/22/2005US20050281816 vaccines; treatment of allergies; three modules: a translocation module to transport MAT molecule into the interior of the cell; a targeting module which directs the MAT molecule to intracellular organelles involved in antigen processing and loading; and an antigen module which contains an allergen
12/22/2005US20050281815 CD40 splice variants and their uses
12/22/2005US20050281814 Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
12/22/2005US20050281813 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
12/22/2005US20050281812 Antibodies to insulin-like growth factor I receptor
12/22/2005US20050281811 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
12/22/2005US20050281810 Variants of alternative splicing
12/22/2005US20050281809 using activated charcoal and ionic or non-ionic exchange resin; for treating patients suffering from both acute and chronic forms of kidney disease; compact, mobile, self-contained device
12/22/2005US20050281807 Use of C-reactive protein to treat immune complex-mediated renal disease
12/22/2005US20050281802 Methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume, glue featuring an adhering moiety coupled to one or more other moieties including a cross-linkable moiety and/or one other adhering moiety; use in treating pulmonary conditions, emphysema, copd
12/22/2005US20050281801 Glue composition for lung volume reduction
12/22/2005US20050281800 Targeting sites of damaged lung tissue
12/22/2005US20050281799 Targeting damaged lung tissue using compositions
12/22/2005US20050281795 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
12/22/2005US20050281789 Transcutaneous and/or transdermal transport of materials
12/22/2005US20050281784 Methods for administering recombinant adeno-associated virus virons to humans previously exposed to adeno-associated virus
12/22/2005US20050281783 Listeria-based EphA2 vaccines
12/22/2005US20050281779 Enhancing immune responses to genetic immunization by using a chemokine
12/22/2005US20050281761 Methods of preventing UVB-induced skin damage
12/22/2005US20050281753 Buccal, polar and non-polar spray or capsule
12/22/2005DE10344545B4 Genetisch modifiziertes Kapsidprotein des Beak and Feather Disease Virus Genetically modified capsid protein of the Beak and Feather Disease Virus
12/22/2005CA2611377A1 Bacterial compositions for the treatment of cancer
12/22/2005CA2573430A1 Anti-perp antibody
12/22/2005CA2570458A1 Antibodies for selective apoptosis of cells
12/22/2005CA2570050A1 Heart and skeletal muscle inflammation (hsmi) virus
12/22/2005CA2570043A1 Env polypeptide complexes and methods of use
12/22/2005CA2569909A1 Vaccine compositions and methods
12/22/2005CA2569788A1 Tumor specific antibody
12/22/2005CA2569692A1 Transferrin receptor antibodies
12/22/2005CA2569662A1 Heparin binding peptide
12/22/2005CA2569590A1 Drug having regulatory cell ligand contained in liposome
12/22/2005CA2569215A1 Screening method using antibody heavy chains
12/22/2005CA2569142A1 Sars vaccines and methods to produce highly potent antibodies
12/22/2005CA2569139A1 Lapatinib with letrozole for use in a treatment of breast cancer
12/22/2005CA2568995E Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
12/22/2005CA2568336A1 Method for treating lupus
12/22/2005CA2568306A1 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody
12/22/2005CA2567477A1 Combination of radio waves and pharmacologically active substances
12/22/2005CA2567081A1 Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them
12/22/2005CA2566651A1 Improved therapeutic agent for inos generating illness
12/22/2005CA2566647A1 Inhibition of macrophage-stimulating protein receptor (ron)
12/22/2005CA2560759A1 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
12/21/2005EP1607745A2 Ligand for G-protein coupled receptor FPRL2 and uses thereof
12/21/2005EP1607402A1 Method for the diagnosis of tumour
12/21/2005EP1607100A1 Remedy for spinal injury containing interleukin-6 antagonist
12/21/2005EP1606633A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
12/21/2005EP1606621A2 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
12/21/2005EP1606411A1 Mutant vesicular stomatitis viruses and use thereof
12/21/2005EP1606409A2 Nogo receptor binding protein
12/21/2005EP1606408A2 Human p53 splice variant displaying differential transcriptional activity
12/21/2005EP1606398A1 Melan-a peptide analogue-virus-like-particle conjugates
12/21/2005EP1606396A2 Methods of promoting the differentiation of stem cells
12/21/2005EP1606391A2 Virulent systemic feline calicivirus
12/21/2005EP1606388A2 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
12/21/2005EP1606314A2 Fc REGION VARIANTS
12/21/2005EP1606012A2 Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy
12/21/2005EP1605974A2 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
12/21/2005EP1605973A1 Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
12/21/2005EP1605972A2 Hiv-peptide-carrier-conjugates
12/21/2005EP1605971A1 Immunogenic composition and methods
12/21/2005EP1605970A2 Anti-cancer virus desensitization method
12/21/2005EP1605894A2 Oxytocin controlled release formulations and methods of using same
12/21/2005EP1605893A2 Trans-membrane-antibody induced inhibition of apoptosis
12/21/2005EP1605763A2 Newcastle disease virus administration
12/21/2005EP1576086A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/21/2005EP1404852B1 Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
12/21/2005EP1402267B1 Chp for use as marker for sepsis
12/21/2005EP1307473B1 Purification of hbv antigens for use in vaccines
12/21/2005EP1276501B1 Method for treatment of tumors using photodynamic therapy
12/21/2005EP1265916B1 Therapeutic anti-cytomegalovirus compounds
12/21/2005EP1223915B1 Dry powder compositions having improved dispersivity
12/21/2005EP1222200B1 Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof
12/21/2005EP1218518B1 Dna polymerase lambda and uses thereof
12/21/2005EP1159426B1 Cloning and expression of haemophilus somnus transferrin-binding proteins
12/21/2005EP0809705B1 Nucleic acid-containing composition, preparation and use thereof
12/21/2005EP0783573B1 Method of enhancing expression of mhc class i molecules bearing endogenous peptides
12/21/2005EP0777474B1 Methods for the treatment of inflammatory joint disease
12/21/2005EP0702692B1 Regulation of antigen presentation
12/21/2005EP0698108B2 Adenoviral vectors of animal origin and use thereof in gene therapy
12/21/2005EP0680331B1 Recombinant virus immunotherapy
12/21/2005CN1711105A Compositions and methods for treating or preventing pneumococcal infection
12/21/2005CN1709506A Horse anteserum preparing and purifying process
1 ... 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 ... 1823